IP Library Granted Patent US 9,345,620
Granted Patent B2
US 9,345,620 · App. 13/098,267 · Granted May 24, 2016

Apparatus and method for providing a laser shot file

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,345,620
App. No.
13/098,267
Granted
May 24, 2016
Kind
B2
Abstract

The invention relates to an apparatus, an algorithm and a method for providing a laser shot file for use in a laser. The laser may be an excimer laser. The shot file may be applied for performing a refractive laser treatment of an eye or for producing a customized contact lens or an intraocular lens. According to the invention information with respect to a desired ablation profile is provided and a first series of laser shot positions is calculated based on the desired ablation profile. A simulated ablation profile is generated using said first series of laser shot positions and using information about pulse characteristics of a single laser shot. The simulated ablation profile is compared with the desired ablation profile and residual structures are determined.

Claims (25)

1. A method for providing a laser shot file for use in a laser, the method comprising:

a) providing information obtained from an eye to be treated,

b) calculating a desired ablation profile based on information obtained from the eye to be treated,

c) calculating a first series of laser shot positions based on the desired ablation profile,

d) generating a first simulated ablation profile using said first series of laser shot positions and using information about pulse characteristics of a single laser shot,

e) comparing the first simulated ablation profile with the desired ablation profile and determining residual structures, and

f) calculating a second series of laser shot positions based on the desired ablation profile and the determined residual structures.

2. The method of claim 1 further comprising:

g) generating a second simulated ablation profile using the second series of laser shot positions and using information about pulse characteristics of a single laser shot,

h) comparing the second simulated ablation profile with the desired ablation profile and determining further residual structures, and

i) calculating a further series of laser shot positions based on the desired ablation profile and the determined further residual structures.

3. The method of claim 2 , comprising repeating steps f) to g) at least one time, wherein the further series of laser shot positions is used as the second series of laser shot positions.

4. The method of claim 1 , wherein the desired ablation profile is calculated based on wavefront information obtained for the eye to be treated, and wherein the wavefront information is preferably given in Zernike coefficients.

5. The method of claim 4 , wherein the wavefront information is given as a wavefront of nth-order, and wherein said first series of laser shot positions is calculated based on said nth-order wavefront.

6. The method of claim 5 , wherein the difference between the first simulated ablation profile and the desired ablation profile is determined by calculating the difference of a simulated wavefront and a desired wavefront to obtain a residual wavefront, wherein the residual wavefront is described with Zernike coefficients.

7. The method of claim 6 , wherein for the following iteration the residual wavefront is added to the previously calculated wavefront.

8. The method of claim 6 , wherein the difference between the simulated wavefront and the desired wavefront is filtered to obtain low and/or high spatial frequencies by calculating Zernike coefficients up to the order N′, and wherein in each iteration step a respective N'th order of the Zernike coefficients is used, and wherein

N′=n− 2*iteration_counter,

with n being the order of the wavefront information and iteration_counter=number of iteration.

9. The method of claim 8 , wherein in each iteration step the corrected wavefront is used for calculating a respective series of laser shot positions, and wherein the iteration steps N′ is less than 3.

10. The method of claim 1 , further comprising:

controlling a laser apparatus responsive to the provided laser shot file.

11. The method of claim 1 , wherein the laser shot file is for use in an excimer laser.

12. The method of claim 1 wherein the laser and the laser shot file are configured for producing a customized contact lens or an intraocular lens.

13. The method of claim 1 wherein the laser and the laser shot file are configured for performing a refractive laser treatment of the eye.

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z.O.O.
Reel/Frame 073637/0222 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 045444/0634) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: BAUSCH & LOMB INCORPORATED; LABORATOIRE CHAUVIN S.A.S.; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 061872/0295 →
OMNIBUS PATENT SECURITY RELEASE AGREEMENT (REEL/FRAME 057821/0800) Recorded Nov 2, 2022
From: THE BANK OF NEW YORK MELLON
To: TECHNOLAS PERFECT VISION GMBH; BAUSCH + LOMB IRELAND LIMITED
Reel/Frame 061884/0514 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 036400/0711) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH
Reel/Frame 061775/0826 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS (REEL/FRAME 045444/0299) Recorded Oct 26, 2022
From: BARCLAYS BANK PLC
To: BAUSCH & LOMB INCORPORATED; TECHNOLAS PERFECT VISION GMBH; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; PF CONSUMER HEALTHCARE 1 LLC; LABORATOIRE CHAUVIN S.A.S.
Reel/Frame 061779/0001 →
SECURITY INTEREST Recorded Oct 5, 2021
From: BAUSCH & LOMB IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; DR. GERHARD MANN CHEM.-PHARM. FABRIK GMBH; TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 057821/0800 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 3, 2019
From: BAUSCH HEALTH IRELAND LIMITED; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT PHARMACEUTICALS LUXEMBOURG S.À R.L.; VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA; VALEANT SP. Z O. O.
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 049672/0652 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Jul 19, 2017
From: TECHNOLAS PERFECT VISION GMBH
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0910 →
SECURITY AGREEMENT Recorded Aug 20, 2015
From: TECHNOLAS PERFECT VISION GMBH; DR. GERHARD MANN CHEM-PHARM. FABRIK GMBH
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 036400/0711 →